Nearly 1 in 6 prostate cancer patients has a germline disease-causing genetic variant.
A recent study in JAMA Oncology examining 3607 men with a personal history of prostate cancer has found that 17% had a germline disease-causing genetic variant. This study has shown that current NCCN guidelines and Gleason scores cannot reliably stratify patients with prostate cancer for the presence or absence of pathogenic germline variants.
The authors have recommended updating genetic testing guidelines to include all men diagnosed with prostate cancer, similar to those for pancreatic, male breast and ovarian cancer.
Genetic testing for hereditary prostate cancer